IDH2 and central nervous system cancer: In high grade gliomas IDH mutations were associated with better survival (median survival wt: 15.0 vs. median survival mut: 64.5 months, P < 0.0001; Supplementary Figure 9A); also 1p/19q co-deletions associated with better survival (P < 0.0001; Supplementary Figure 9B).